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ABSTRACT
The genes for mitoribosomal protein S12 (Mrps12)
and mitochondrial seryl-tRNA ligase (Sarsm and
Sars2) are oppositely transcribed from a conserved
promoter region of <200 bp in both human and
mouse. Using a dual reporter vector we identified an
array of 4 CCAAT box elements required for efficient
transcription of the two genes in cultured mouse
3T3 cells, and for enforcing directionality in favour
of Mrps12. Electrophoretic mobility shift assay
(EMSA) and in vivo footprinting confirmed the
importance of these promoter elements as sites of
protein-binding, and EMSA supershift and chromatin
immunoprecipitation (ChIP) assays identified NF-Y as
the key transcription factor involved, revealing a
common pattern of protein–DNA interactions in all
tissues tested (liver, brain, heart, kidney and 3T3
cells). The inherently bidirectional activity of NF-Y
makes it an especially suitable factor to govern
promoters of this class, whose expression is linked
to cell proliferation.
INTRODUCTION
The machinery of mitochondrial protein synthesis is partly
encoded by the nuclear genome and partly by mitochondrial
DNA (mtDNA). In vertebrates, the contribution of the latter
is exclusively the ribosomal and transfer RNAs. All mitoribo-
somal proteins, aminoacyl-tRNA ligases, translation factors
and chaperones are nuclear coded [for review see Ref. (1)].
In mammals, two genes for components of the mitochondrial
translational apparatus, encoding mitoribosomal protein
S12 (Mrps12) and the mitochondrially localized isoform of
seryl-tRNA ligase (Sarsm or Sars2), are encoded by oppo-
sitely transcribed genes that share a common, bidirectional
promoter region of <500 bp (2,3). The genes are located on
chromosome 19 in human and chromosome 7 in mouse (2,4).
Bidirectional promoters are a common feature of mamma-
lian genomes (5,6), and microarray studies indicate that the
majority of such gene pairs are co-regulated. However, rela-
tively few studies have addressed the mechanisms of
transcriptional regulation that govern such promoters, and
ensure that both genes are efﬁciently and stably transcribed.
In the case of human MRPS12 mRNA, previous studies by
ourselves (7,8) and others (9) indicated that three classes
of transcript are produced by alternate splicing within the
50-untranslated region (50-UTR). One splice variant is suscep-
tible to translational regulation in response to cellular growth
status (8), even though it lacks the 50-terminal oligopyrimi-
dine tract characteristic of cytoplasmic ribosomal protein
mRNAs that are regulated in this manner. However, the dif-
ferent splice variants of MRPS12 mRNA appear to be
expressed at similar relative levels in all tissues analysed,
suggesting that they are not selectively transcribed. The
SARSM mRNA has not been studied in detail, but it appears
to comprise a single species with a very short 50-UTR (27 nt).
The two genes show a very similar organization in mouse,
although one Mrps12 splice variant appears to be absent,
and the Mrps12 ﬁrst intron is slightly shorter.
Elucidating the ways in which genes of the apparatus of
mitochondrial protein synthesis are regulated also has a bio-
medical dimension. Mutations affecting the mitochondrial
translational apparatus, including the seryl tRNAs (10) and
at least one mitoribosomal protein, MRPS16 (11) have been
implicated in disease, and mutations in the Drosophila homo-
logue of MRPS12 also produce a mitochondrial-disease-like
phenotype (12).
In mammals, nuclear genes for components of the
mitochondrial oxidative phosphorylation (OXPHOS) system
are regulated by a variety of transcription factors, most
notably by nuclear respiratory factors NRF-1 and NRF-2,
which have single or multiple binding sites in the promoters
of many nuclear genes for subunits of the OXPHOS
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gene expression [for review see Ref. (13)]. Possible binding
sites for NRF-1 and NRF-2 were noted in the SARSM/
MRPS12 promoter region by Johnson et al. (9), although
the former lie within the SARSM coding sequence and ﬁrst
intron. NRF-2 and especially NRF-1 also regulate a large
number of other genes which need to be highly expressed
in proliferating cells. In yeast there are no known homologues
of NRF-1 or NRF-2, but the CCAAT box-binding transcrip-
tion factor Hap2/3/5 appears to be the main activator of
transcription of nuclear genes involved in mitochondrial
biogenesis and OXPHOS (14–16)
In order to establish the functional elements involved
in transcription from the bidirectional promoter of MRPS12
and SARSM we decided initially to focus strictly on the
intergenic region and 50-UTR segments, i.e. up to the start
codon of each gene, and to study the mouse rather than the
human promoter, with a view to using the knowledge later
to manipulate expression in the whole organism. We initially
aligned and compared the promoter region from mouse
and human, in order to identify conserved blocs of sequence.
We then cloned the mouse sequence into a dual luciferase
reporter and carried out a deletion analysis to localize the
main regulatory elements. This was followed up by
electrophoretic mobility shift assay (EMSA), in vivo foot-
printing and chromatin immunoprecipitation (ChIP) assays,
to test for evidence of protein-binding within the putative
regulatory elements, and by further reporter assays in which
such sites were mutated. These studies revealed the impor-
tance of an array of four CCAAT box elements interacting
with the transcription factor NF-Y, the mammalian homo-
logue of yeast Hap2/3/5. The evidence for involvement
of NRF-2 and other factors was less clear, and we propose
that these act most likely as accessory factors to boost
transcription.
NF-Y exhibits an inherently bidirectional activity, capable
of recognizing its core binding site sequence in either orienta-
tion, i.e. as CCAAT or as ATTGG on the coding strand.
We propose that this makes it an especially suitable factor
to govern bidirectional promoters of this class, especially
when their expression is linked, like that of many genes
involved in mitochondrial biogenesis, to cell proliferation.
MATERIALS AND METHODS
Cells and cell culture
NIH 3T3 cells were cultured in DMEM (Cambrex)
supplemented with 10% FBS, 50 U/ml penicillin (Cambrex)
and 50 mg/ml streptomycin (Cambrex). All cells were
maintained at 37 Ci n5 %C O 2.
RNA extraction
RNA was extracted from cells at 80% conﬂuence using
TRIzol reagent (Invitrogen) according to the manufacturer’s
recommended conditions, with resuspension in 30 ml
nuclease-free water per 10 cm plate of cells. Treatment
with 15 U RNase-free DNAse I (Amersham Biosciences)
was carried out for 1 h at 37 C in a ﬁnal volume of 50 ml
of manufacturer’s recommended buffer. RNA was recovered
by phenol–chloroform extraction, ethanol precipitation and
ﬁnal resuspension in 30 ml nuclease-free water, and its purity
and integrity were checked electrophoretically.
Reporter constructs
A dual luciferase reporter vector was constructed by
recloning the entire coding sequence of ﬁreﬂy luciferase,
including the SV-40 late poly(A) region, from the vector
pGL3-basic (Promega) into the vector phRL-null (Promega),
as an NcoI–SalI fragment. The resulting vector (pFRL) con-
tains ﬁreﬂy and Renilla luciferase reporter genes oriented
such that transcription is in opposite directions, with a unique
NcoI site (CCATGG) between them, which provides the in-
frame start codon in both directions. The Mrps12-Sarsm
intergenic region was ampliﬁed with the following chimeric
primers, using a mouse genomic DNA clone as template
(NcoI restriction sites in bold, non-templated nucleotides
underlined, all sequences 50–30), Mrps12: CATGCCATGG-
CTCGCCGCCTGCAGCGTCCC, Sarsm_F: CATGCCATG-
GCTTGGAGTGGAAACAAGAAGTCAC. The PCR prod-
uct was digested with NcoI and then cloned into NcoI-cut
pFRL, generating clones in both orientations. To create a
deletion series from the wild-type template, either of the
same terminal primers was used together with the deletion
primers indicated in Supplementary Figure 1b (Mrps12 with
the primers designated Sarsm_F7, Sarsm_F2 etc. to created
deletions S7, S2 etc. Sarsm_F with primers Mrps_PF1 and
Mrps_PF2 to create deletions M1 and M2, respectively),
with each product cloned into the NcoI site of pFRL using
a similar strategy as for the wild-type promoter. To create
point mutants of the dual reporter construct, a two-round
mutagenic PCR strategy was employed, except for those
cases where the mutations to be introduced were within 40
bp of the end of the intergenic region, and could thus be
created in a single mutagenic step using modiﬁed terminal
primers. Full details of primers are available in Supplemen-
tary Table 1. In each case the ﬁnal PCR product, following
digestion with NcoI, was cloned into the NcoI site of
pFRL. Every construct was veriﬁed by sequencing in both
directions. A b-galactosidase reporter construct (17) was
kindly provided by Dr H. Renkema.
Transfections and reporter assays
Cells grown to 80% conﬂuence were transfected in 6-well
plates using TransFectin Lipid Reagent (Bio-Rad) according
to the manufacturer’s instructions, with 0.25 mg of DNA from
each luciferase construct together with 0.25 mg of DNA of the
b-galactosidase control vector.
After 24 h ﬁreﬂy and Renilla luciferase activities were
assayed in cell lysates using the Dual Luciferase Reporter
Assay System (Promega) and a BioORBIT 1254 luminova
luminometer. b-galactosidase activity was determined in
50 ml aliquots of the same lysates by the addition of 50 ml
ONPG solution (2-nitrophenyl b-D-galactopyranoside)
and 10 ml of 500 mM NaCl, 100 mM MgCl2, 100 mM
b-mercaptoethanol, with incubation at 37 C for 1 h and
measurement of A420. Luciferase activities were normalized
for transfection efﬁciency using b-galactosidase activity.
See legend to Figure 2 for further details.
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First strand cDNA was synthesized from 5 mg cellular RNA
using M-MuLV reverse Transcriptase (Fermentas) under
manufacturer’s recommended conditions, using 0.5 mg
oligo(dT) primer. After treatment with boiled RNase (Roche)
the cDNA was used in PCR in a 5-fold dilution series in the
presence of SYBR Green (Qiagen) for ﬂuorescent quantitation
of the product, using the following gene-speciﬁc primers
(all sequences shown as 50–30). For Sarsm, SARSM 8:
CTTTCAGGGACCTTCCAGTCA and SARSM 4: CCGT-
CAAGATCTCCACCTGC; for Hprt, mHPRT_R1: CACAG-
GACTAGAACACCTGC and mHPRT_F1: GTTGGATACA-
GGCCAGACTTTGT; for Mrps12, Mrps55: TTCCATGGC-
CACCCTGAACCAG and Mrps32: CAGCACTTGCGGTT-
GGCGGAG. Cycle parameters were: denaturation at 94 C
for 15 s (initial denaturation at 95 C for 10 min), annealing
for 10 s at 57 C (for Hprt)o r5 5  C for Sarsm and Mrps12,
extension at 72 C for 20 s, 55 cycles (Light cycler, Roche).
EMSA
Nuclear extracts were prepared from NIH 3T3 cells
essentially as described by Wadman et al. (18), except that
KCl was substituted for NaCl in Buffer C, and Pepstatin
was omitted. Nuclear extracts were prepared from mouse
liver as described by Sun et al. (19). EMSA probes were syn-
thesized by PCR, using as template the wild-type or mutated
reporter constructs of the Mrps12-Sarsm intergenic region,
plus primers as indicated in Supplementary Table 2. In
each case the identity of the product was veriﬁed by sequenc-
ing before proceeding. After dephosphorylation with calf
intestinal alkaline phosphatase (Fermentas) under manufac-
turer’s recommended conditions, 0.6 ng of probe DNA was
labelled using 8 U of T4 Polynucleotide Kinase (Fermentas)
in a 15 ml reaction containing 10 mCi of [g-
32P]ATP
(Amersham,  6000 Ci/mmol) for 1 h at 37 C. The volume
was adjusted to 100 ml by the addition of water, and 20 ml
EMSA reactions were set up in binding buffer (25 mM
HEPES-KOH, 12.5 mM MgCl2, 20% glycerol, 0.1%
Tween-20, 2 mM DTT, 500 mM KCl and pH 7.9) using
1 ml of probe, 5 mg of nuclear extract (protein concentration
determined using Bradford assay), 5 mg BSA (Fermentas) and
5 mg non-speciﬁc competitor, i.e. Poly(dI–dC)·Poly(dI–dC) or
Poly(dA–dT)·Poly(dA–dT) (Amersham). Supershift reactions
contained, additionally, 1 ml of the relevant antibody solution
(2 mg/ml, all from Santa Cruz Biotechnology): CBF-B (G-2),
i.e. NF-Y, mouse monoclonal IgG, C/EBP, rabbit polyclonal
IgG, C-JUN, rabbit polyclonal IgG. Supershift reactions were
preincubated for 20 min at room temperature prior to addition
of the probe. After incubation at room temperature for 30 min
reactions were analysed on 5% polyacrylamide gels run at
4 C in TBE buffer at 6 V/cm for 1 h, followed by 10 V/cm
for a further 3–5 h depending on the fragment size, before
exposure to X-ray ﬁlm.
In vivo footprinting
NIH 3T3 cells were grown to 80% conﬂuence. After washing
with serum-free medium, cells were treated for 6 min at room
temperature with freshly prepared serum-free medium
containing 0.2% (v/v) DMS. The cells were rapidly washed
in HBSS (20), detached by trypsinization, and nuclei and
DNA isolated as described by Pfeifer and Tornaletti (21).
Footprinting from mouse liver, kidney, brain and heart was
carried out according to Lacronique et al. (22). Control
DNA (50 mg) was methylated in vitro according to Maxam
and Gilbert (23). After two 80% ethanol washes, DNA
samples (both in vivo- and in vitro-methylated) were dis-
solved in 100 ml 10% piperidine and incubated for 30 min
at 82 C. The reaction products were frozen on dry ice,
ethanol precipitated, washed twice with 80% ethanol and
dissolved in water at 0.4 mg/ml. The size of the fragments
was veriﬁed to be in the range 100–500 bp by 1.5% alkaline
agarose gel electrophoresis (24). Analysis of methylated sites
was carried out by ligation-mediated PCR, as described by
Angers et al. (25), involving sets of three gene-speciﬁc
primers as listed in Supplementary Table 3 (the ﬁrst for
primer-extension, the second for PCR, the third for the ﬁnal
labelled primer-extension by cycle synthesis). The universal
LM-PCR linker was prepared by annealing of oligonu-
cleotides Li1 (50-GCGGTGACCCGGGAGATCTGAATTC-
30) and Li2 (50-GAATTCAGATC-30). Li1 was also used as
one primer in the PCR step.
ChIP assays
NIH 3T3 cells were grown to 80–90% conﬂuence in 10 cm
culture plates. After cross-linking for 10 min with 1%
formaldehyde in serum-free medium, phosphate-glycine
buffer was added to a ﬁnal concentration of 0.125 M and
cells were washed twice with ice-cold phosphate-buffered
saline (PBS). Nuclei were isolated as for EMSA and lysed
essentially as described by Spencer et al. (26), except that
an SDS concentration of 0.1% instead of 1% was used. The
chromatin lysate was sonicated on ice to an average DNA
length of 600 bp. Chromatin was pre-cleared with blocked
Sepharose A and ChIP assays were performed as described
by Spencer et al. (26), using 8 mg of either the anti-NF-Y
mouse monoclonal antibody described above or, as negative
control, M2 anti-FLAG  mouse monoclonal (Stratagene).
The ﬁnal PCR step used primers GGAGTGGAAACAA-
GAAGTCACTCAT and CTGAGTAGGCCCCCAAGGACC
(both shown 50 to 30), which amplify the fragment spanning
np 4–349 of the sequence shown in Supplementary Figure
1b. Following an initial 5 min denaturation at 95 C, PCR
involved 32 cycles of the following: denaturation for 1 min
at 94 C, annealing for 30 s at 59 C, extension for 30 s at
72 C. Reaction products were analysed on a 1.5% agarose-
TBE gel stained with ethidium bromide and visualized
under ultraviolet (UV) light.
RESULTS
Organization of the mouse Sarsm-Mrps12
intergenic region
The intergenic region between the mouse genes Sarsm and
Mrps12 was compared with the homologous region of
the human genome. The predominant 50 ends of transcripts
of the two genes were also compared between the species,
using publicly available EST data. As summarized in
Figure 1 (see also Supplementary Figure 1), the overall
organization of the region is highly preserved between the
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extremely short (26 nt) and largely identical with its human
counterpart. From ESTs there is no support in either species
for a longer 50-UTR, as reported for human SARSM by
Yokogawa et al. (2), NCBI database entry NM_017827,
reconstructed from multiple EST clones and in-house
RT–PCR]. We thus take the latter to be a very minor species.
The non-transcribed portion of the intergenic sequence is
184 bp in mouse (7 bp longer in human). The ﬁrst part of
this sequence (i.e. nearest to Sarsm) is dissimilar between
the two species, except for the presence in both cases of
two copies of the CCAAT box sequence, with slightly differ-
ent spacing. This is followed by a 147 bp sequence that is
69% identical between human and mouse, which extends to
the region of the ‘downstream start site’ for Mrps12
(see below). This region contains two additional CCAAT
box elements which are identically spaced in the two organ-
isms, as well as the NRF-2 binding site identiﬁed previously
by Yokogawa et al. (2), which is conserved in mouse.
Two clusters of start sites for Mrps12 are found in virtually
identical positions in the two organisms. The ﬁrst overlaps
(human) or immediately follows (mouse) the putative NRF-2-
binding site, and gives rise to transcripts which use a splice
donor  40 nt downstream, removing a 211 nt intron [277 nt
in humans, but also with an alternative upstream splice accep-
tor, see Ref. (8)]. The intron is less similar in the two species
apart from a 60 bp segment located towards the 30 side in
mouse, but more centrally placed in human, which shows
77% identity, plus the terminal polypyrimidine tract and ter-
minal splice acceptor region. A second cluster of Mrps12
transcriptional start sites coincides approximately with the
start of the intron, which is thus preserved in these mRNAs
as a longer 50-UTR. Previous data (8) indicated that the
shorter (spliced) mRNAs are regulated translationally in
response to growth signals in human cells. Overall, the
sequence comparison reveals a very similar organization of
the bidirectional promoter region of these two genes in
mouse and human genomic DNA, and a high degree of
sequence conservation of the region lying between their
major transcriptional start sites.
Relative expression levels of Sarsm and Mrps12
Quantitative RT–PCR (q-PCR) was used to estimate the
steady-state levels of Sarsm and Mrps12 mRNAs in mouse
3T3 cells, relative to that of Hprt as a standard. Based on par-
allel reactions at different dilutions, the level of Mrps12
mRNA was estimated as 96 + 11% that of Hprt mRNA,
whereas Sarsm mRNA was 78 + 16% as abundant as Hprt
mRNA. The steady-state levels of the two mRNAs are thus
very similar.
Reporter analysis of the Sarsm-Mrps12
intergenic region
In order to test whether the intergenic region contains
elements essential for transcription in the two directions,
we constructed a dual reporter vector (see Materials and
Methods) in which the transcriptional activities in the two
opposite directions could be tested simultaneously via the
readouts of ﬁreﬂy and Renilla luciferase. We initially inserted
the full intergenic region (all 480 bp lying between the two
start codons) into the reporter vector in both orientations, in
order to allow us to determine the relative activities of the
promoter in each direction. As indicated in Figure 2, as a
result of comparing the expression of each reporter in the
two oppositely oriented constructs, transcriptional activity
Figure 1. Molecular architecture of the Mrps12-Sarsm bidirectional promoter region in mouse. For complete sequence and additional data see Supplementary
Figure 1. Numbering commences at the nucleotide pair immediately upstream of the Sarsm start codon. (a) Based on EST data, mouse Sarsm mRNA exists in a
single isoform, whereas Mrps12 mRNA has at least two major splice variants as shown, with different transcription starts. (b) Sequence comparison with the
homologous region of human genomic DNA, broken arbitrarily into segments according to their degree of sequence identity with mouse genomic DNA, as
indicated.
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than in the Sarsm direction, when tested by transfection into
exponentially growing 3T3 cells. A series of deletion
constructs was then made, in order to test which portions
of the intergenic region were important for expression
globally or directionally. The ﬁrst two constructs tested
(M1 and S7, see Figure 2) involved very short deletions of
the regions upstream of the two start codons, which were ini-
tially intended to ﬁlter out any effects due to loss of
translation-regulatory sequences. Although neither of these
deletions produced dramatic effects, gene expression in
both directions was affected, suggesting that transcriptional
regulatory elements encompass the entire region.
Deleting further upstream from the Sarsm start codon
produced a complex series of effects. Removal of the
Sarsm mRNA start site and CCAAT box I resulted in a
drop in expression in the Mrps12 direction and an increase
in the Sarsm direction, but with little overall change in total
expression. This suggests that the region contains an element,
which inﬂuences the direction more than the overall amount
of transcription, favouring Mrps12. Deletions as far as the
boundary of CCAAT box III or beyond virtually abolished
expression in the Sarsm direction, but Mrps12 was affected
only mildly (Figure 2, constructs S7, S2 and S3) until the
boundary of CCAAT box IV was reached (Figure 2, construct
S4). Removal of both of the major transcriptional start sites
(for Sarsm plus the upstream start for Mrps12), as well as
the entire region between them containing all four CCAAT
boxes, almost completely abolished expression (Figure 2,
construct S5). The construct (S4) in which the putative
NRF-2 binding site was preserved was only slightly more
transcriptionally active than the one in which it was removed
(S5), with almost no transcription in the Sarsm direction in
either case, and only 18% of the wild-type level of expression
in the Mrps12 direction for construct S4, compared with 6%
for S5. However, this does not exclude the possibility that the
NRF-2 site contributes to transcriptional activity when the
CCAAT boxes or other upstream elements are still present.
Surprisingly, deletion of the region of the splice acceptor
for the optional ﬁrst intron of Mrps12 mRNA led to a signiﬁ-
cant increase in expression in both directions, indicating the
presence of a negative regulatory element. Deletion analysis
thus identiﬁed two kinds of regulatory element in the bidirec-
tional promoter region: one or more (positively acting)
Figure 2. Reporter analysis of the Mrps12-Sarsm bidirectional promoter. The promoter region (from 1 to 480 nt, i.e. immediately flanked by the two start codons)
was cloned into NcoI site of the customized vector pFRL, illustrated schematically at top right, in both orientations. A set of deletions was also created, as shown.
The main features of the promoter region are reproduced from Figure 1, and the deleted segment in each construct is indicated as a dotted line (see Supplementary
Figure 1b for details). Expression in the two directions was calculated based on luciferase activities after transfection, as follows. First, activities were normalized
to that of b-galactosidase in the same extracts, to correct for transfection efficiency. Renilla luciferase activity was then scaled to firefly luciferase activity by
comparing the mean activities of the two reporters in the wild-type construct cloned in the two opposite directions, based on a set of replicate experiments.
Finally, expression was normalized against that supported by the wild-type promoter in the Mrps12 direction (¼ 100 arbitrary units, a.u.), which was measured
afresh in every set of experiments. Plotted data are means ± SD from at least three independent transfections. Background luciferase activities of the empty pFRL
vector, compared with the wild-type promoter, were 0.2% (Renilla) and 1.5% (firefly).
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sites, which also inﬂuence the relative directionality of
transcription, as well as a negatively acting element within
the ﬁrst intron of Mrps12.
Analysis of protein-binding sites by EMSA
Reporter studies having indicated the presence of various
cis-acting elements in the Sarsm-Mrps12 intergenic region,
we then investigated protein-binding to such sites using
EMSA. Overlapping probes were synthesized and reacted
with 3T3 cell nuclear protein extracts in the presence of
each of two different polynucleotide competitors.
Clear signatures of speciﬁc protein-binding were inferred
for three of the four fragments (Figure 3: see also Supplemen-
tary Figures 2–5 for full gel images). The speciﬁc complexes
(denoted A1 and B1 in Figure 3) formed by fragments A and
B, each of which contains two of the CCAAT boxes, were
reciprocally competed, indicating that they most likely
involved the same protein(s). Fragment C gave one clear
complex (denoted C1 in Figure 3), which was competed
only by fragment C. Fragment D gave no signal indicative
of sequence-speciﬁc protein-binding.
To localize the sequences critical for binding, we carried
out EMSA competition experiments using an overlapping
series of unlabelled, double-stranded oligonucleotide com-
petitors. As summarized in Figure 3, (see also the primary
data on which Figure 3 is based, i.e. Supplementary Figure 6),
oligonucleotide 12 alone was able to compete with fragment
C for the formation of complex C1, localizing the region criti-
cal for binding to the sequence spanning the ﬁrst splice
acceptor and downstream transcriptional start of Mrps12.
The CCAAT box containing fragments A and B showed an
unexpectedly complex pattern of oligonucleotide competi-
tion. The formation of complex B1 was strongly inhibited
by oligonucleotide 9, containing CCAAT box IV, and also,
though less strongly, by oligonucleotide 7, containing
CCAAT box III. The formation of complex A1 was also
inhibited strongly by oligonucleotide 9 and moderately by
oligonucleotide 7, even though CCAAT boxes III and IV
lie outside of Fragment A. However, oligonucleotides 5 and
2, containing, respectively, CCAAT boxes II and I gave,
respectively, a weaker or extremely weak inhibition of the
formation of complex A1. No competition was evident
form any oligonucleotide other than those containing the
CCAAT box elements. In all cases we were able convinc-
ingly to detect only a single, speciﬁc complex. The simplest
interpretation is that the strongest binding is to the region of
CCAAT box IV, but that the binding activity does not reside
in single CCAAT boxes, rather in the array as a whole.
Figure 3. EMSA analysis of protein-binding to the bidirectional promoter region. The main features of the promoter region are reproduced from Figure 1, aligned
with the four fragments tested in the assays (for fragment details Supplementary Table 2). The right hand panels show summarized data for each fragment,
abstracted from Supplementary Figures 2–5, where full details of the gels are shown. In each case, only the major complexes resistant to both of the non-specific
competitors, i.e. a   poly(dA–dT)·(dA–dT) and i   poly(dI–dC)·(dI–dC), are shown, designated A1, B1 and C1 as in Supplementary Figures 2–4. No specific
EMSA signal was seen for fragment D (see Supplementary Figure 5). Competition from unlabelled DNA fragments in each series was 1-, 25- and 80-fold mass
excess. The results of competition from oligonucleotides 1–16 (see Supplementary Table 2) are summarized at bottom left, based on EMSA data shown in
Supplementary Figure 6. White boxes indicate oligonucleotides, which showed no competition (even at >100-fold molar excess), grey boxes those that showed
weak competition, and black boxes those that showed strong competition at >25-fold molar excess.
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no change was detected by EMSA in protein-binding to
fragment B (Figure 4b). Destruction of CCAAT box IV
did, however, reduce the efﬁciency of binding, and the com-
plex migrated slightly faster. Destruction of both CCAAT
boxes III and IV completely abolished speciﬁc protein-
binding to fragment B. Similarly, destruction of CCAAT
box II had almost no effect on the complex formed by frag-
ment A (Figure 4b), although in this case, destruction of
CCAAT box I abolished speciﬁc binding, suggesting that
CCAAT box II is at most an accessory element.
In support of this, fragments containing CCAAT boxes I,
III or IV individually formed similar complexes (Supplemen-
tary Figure 7b), whereas the fragment containing only
CCAAT box II formed a faster-migrating complex. CCAAT
box I was able to compete efﬁciently against CCAAT box II
for the formation of this complex, whereas competition was
much weaker in the reciprocal reaction. The complex formed
by the fragment containing CCAAT box IV was resistant to
competition from the other CCAAT box containing
fragments, whereas that formed by CCAAT box III was
moderately competed by CCAAT box IV (Supplementary
Figure 7b).
An EMSA probe (fragment E) containing all four CCAAT
boxes formed a single major complex (Figure 4c, Supplemen-
tary Figure 7c). Destruction of the CCAAT boxes in various
permutations conﬁrmed a hierarchy of binding strengths.
CCAAT box I or IV on their own yielded complexes of
similar but slightly more discrete mobility than the full
fragment (Figure 4c). The CCAAT box I complex also
migrated slightly faster, consistent with the possibility that
the mobility of the complexes might reﬂect different degrees
of distortion by DNA bending, dependent on the location of
the binding site within the fragment (although other explana-
tions are possible). CCAAT box III, the most centrally
located within the fragment, was, on its own, weakly able
to support the formation of an even more retarded complex.
CCAAT box II alone was unable to support the formation
of a discrete complex, although a residual smear was always
seen. The presence of CCAAT box II also had little effect on
the mobility of the complexes formed by the other CCAAT
boxes. The combinations of CCAAT box I and IV (or I and
III) yielded less discrete mixtures of complexes similar to
those produced by the full fragment.
All the above complexes are inferred to represent mutually
exclusive occupancy of only one of the CCAAT boxes. In
lower percentage gels a more retarded complex was sometimes
seen (e.g. Figure 4b), although antibody supershift experiments
suggest that it contains a distinct protein composition rather
than multiple occupancy of the CCAAT boxes.
Antibody supershift experiments demonstrated that the fac-
tor binding to the CCAAT box array was NF-Y (Figure 4d,
Figure 4. EMSA analysis of protein-binding to CCAAT box array. (a) Schematic map showing locations of the four CCAAT boxes and probe fragments used.
Numbering as in Supplementary Figure 1b. (b and c) EMSA using wild-type and mutant versions of fragments A, B and E, created by PCR from mutated reporter
constructs as detailed in Supplementary Table 1. The intact CCAAT boxes in each fragment are denoted with Arabic numerals. Increasing by 2-fold the amount
of nuclear extract did not result in additional complexes being formed (data not shown). (d) Antibody supershift EMSA using wild-type and mutated fragment E,
with intact CCAAT boxes as denoted by Arabic numerals, and antibodies as indicated. (e) Antibody supershift EMSA using nuclear extract from mouse liver,
probe fragments and antibodies as indicated.
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supershifted the complex formed by the fragment containing
all four CCAAT boxes (Figure 4d) or by any of CCAAT
boxes I, III or IV individually (Supplementary Figure 7d
and e). No supershift was observed with an antibody against
c-Jun (Figure 4d and e, Supplementary Figure 7f), despite
the presence of two regions of partial homology to the
AP-1 binding site consensus in the promoter region (see
Supplementary Figure 1b).
With an antibody against C/EBP a weak supershift was
seen in at least three separate experiments. However, the
signals were clearly seen only for large fragments containing
CCAAT boxes III and IV. The supershift was most convinc-
ingly seen when CCAAT box IV was destroyed by mutagene-
sis (Figure 4d). The band which was supershifted by the
antibody against C/EBP appeared to be the same one which
was supershifted by the antibody against NF-Y. We tenta-
tively conclude that, in vitro, C/EBP interacts weakly or
transiently with this complex, perhaps via a second CCAAT
box unoccupied by NF-Y.
Using nuclear extract from mouse liver we were able to
obtain a similar pattern of protein-binding to fragments
containing the CCAAT boxes (Figure 4e). Once again, a
clear supershift was obtained using an antibody against
NF-Y. However, the antibody against C/EBP also produced
a supershift of the complex formed by the fragment contain-
ing CCAAT boxes III and IV even when CCAAT box IV
remained intact.
The results of EMSA experiments can be summarized as
follows: sequence-speciﬁc protein-binding was detected to
the CCAAT box array and to a sequence element within
the Mrps12 ﬁrst intron. The protein-binding to the CCAAT
box array in vitro was identiﬁed as NF-Y. At least in nuclear
extracts from some tissues, C/EBP also appeared to be
present within the same complex.
Analysis of protein-binding in vivo
In vivo footprinting was used to conﬁrm occupancy of the
CCAAT boxes and to probe protein–DNA interactions
in vivo in the surrounding region, in both cultured cells and
solid tissues. Signals indicating occupancy of all four
CCAAT boxes (protection of both guanines in the core
sequence) were detected (Figure 5a and b). In addition, we
detected protected guanines in the regions between CCAAT
boxes I and II, and between CCAAT boxes III and IV
Figure 5. In vivo footprinting analysis of the CCAAT box array and surrounding elements. (a–d) Footprints from NIH 3T3 cells (3T), mouse liver (Li), brain
(Br), kidney (Ki) and heart (He), alongside mouse genomic DNA control. Protected nucleotides indicated by filled circles, hyperaccessible nucleotides by open
circles. Signals mapping at CCAAT boxes I, II, III and IV denoted by Roman numerals; those mapping at the putative NRF-2 binding site so indicated. Dotted
lines indicate the positions of CCAAT boxes where G residues are located on the opposing strand. Primer sets as detailed in Supplementary Table 3. (e) Summary
of footprinting data in the first 200 bp of the intergenic region. Bold arrows indicate the major transcriptional starts of the two genes. (f) ChIP analysis of the
Mrps12-Sarsm promoter region. PCR used as templates the chromatin immunoprecipitates obtained using anti-NF-Y antibody (N), a negative control antibody
(anti-FLAG , F), no antibody ( ) or the input chromatin. The prominent 346 bp product was obtained only after immunoprecipitation with the specific antibody.
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is recruited to the region in vivo. We also found clear protec-
tion of the NRF-2 binding site (Figure 5d, Supplementary
Figure 8c), even though no binding to the region was
detected by EMSA in vitro. This protection might represent
a stable association of components of the core transcrip-
tional machinery with the adjacent start site for Mrps12.
Alternatively it may indicate a bona ﬁde site for NRF-2-
binding in vivo, even though the site was not accessible
in naked DNA in vitro, possibly because of NF-Y binding
to the adjacent region. A number of hyperaccessible guanines
were detected, in particular near the transcriptional start
site of Sarsm, where they were closely interspersed with
protected nucleotides, indicative of a distorted DNA struc-
ture. Hyperaccessible sites were found also between some
of the CCAAT boxes. The two regions where there was inter-
spersion of protected and hyperaccessible nucleotides, i.e.
between CCAAT boxes III and IV and upstream of
CCAAT box I (Figure 5e), were those which showed a partial
similarity with the consensus binding site for AP-1 (Supple-
mentary Figure 1b), even though no protein-binding in
these regions was detected in vitro, and EMSA supershift
experiments with the antibody against c-Jun were negative
(Figure 4).
The footprinting patterns were essentially indistinguishable
between cultured cells and the four solid tissues analysed
(liver, brain, kidney and heart). No protected sites were
detected by in vivo footprinting in the region of oligo-12
(Supplementary Figure 8), although several nucleotides in a
nearby region of fragment C were slightly hyperaccessible
to methylation.
To conﬁrm the binding of NF-Y to the bidirectional
promoter region in vivo, we carried out ChIP assays using
the antibody against NF-Y. The procedure consistently
yielded a strong ﬁnal PCR product, using primers speciﬁc
for the Mrps12-Sarsm promoter (Figure 4f), whereas negative
controls either gave no detectable product (when no antibody
was included in the reaction) or only a very weak product,
when a different antibody (against the FLAG epitope) was
used under the same conditions. Mock reactions in which
the chromatin was omitted also gave no product (data not
shown), conﬁrming that the antibody and other reagents
were free from contamination.
The analysis of protein-binding to the bidirectional
promoter in vivo, based on in vivo footprinting and ChIP
assays, thus indicated occupancy of the CCAAT boxes (by
NF-Y), and also of the NRF-2 binding site, as well as possible
protein-binding at other sites.
Effects of CCAAT boxes and other sequence elements
on promoter activity
Our initial promoter deletion analysis indicated the impor-
tance of the CCAAT box region for transcriptional activity,
as well as the existence of a putative repressor-binding site
in the region of the Mrps12 splice acceptor/intron1. To
analyse the effects of these and other sequence elements in
ﬁner detail, we constructed a series of point mutants of the
promoter region, using the dual luciferase reporter vector,
and tested their effects on luciferase expression (Figure 6,
Supplementary Figure 9, Supplementary Table 1).
We replaced the central CA of each CCAAT box, both
individually and in all combinations, by TG. Destruction of
either CCAAT box I or IV resulted in a substantial change
in the directionality of transcription, whereas loss of
CCAAT boxes II and/or III caused only a modest drop in
the total amount of expression. Loss of CCAAT box I,
whether alone or in combination with CCAAT boxes II or
III, resulted in a large relative upregulation of transcription
in the Sarsm direction (Figure 6 and Table 1), whereas loss
of CCAAT box IV had the opposite effect. Destruction of
all four CCAAT boxes reduced the total amount of expres-
sion to about 15% of the wild-type level, but the effect was
more marked on Mrps12 than on Sarsm. In other words, the
CCAAT box array as a whole seems to enforce directionality
in favour of Mrps12.
CCAAT box I alone gave substantial transcriptional
activity favouring the Mrps12 direction, which was enhanced
by the presence of CCAAT box II. CCAAT box IV alone
gave substantial transcriptional activity favouring the Sarsm
direction, and the additional presence of CCAAT boxes II
and/or III did not affect the directional bias. When only
CCAAT box II or III was left intact, transcription was
supported at  30–40% of wild-type levels, with a residual
bias in favour of Mrps12.
We also analysed the effects of making point mutations at
other sites identiﬁed from in vivo footprinting as having
potential roles in transcriptional regulation: abolition of the
putative NRF-2 binding site reduced total expression <50%
of wild-type, without affecting the directional bias
(Figure 6). Abolition of the AP-1 binding site similarity in
either or both of the two regions where protected and
hyperaccessible sites were adjacent resulted in only a small
(<30%) drop in transcription and again no change in its direc-
tionality (Figure 6). Mutations introduced at many other sites
in the promoter region, which were identiﬁed bioinformati-
cally as potential binding sites for various transcription
factors, had similarly modest effects (Supplementary Figure
9), with one notable exception. A cluster of mutations
(Mu3), introduced within the end of the phylogenetically
conserved core of the Mrps12 ﬁrst intron, adjacent to the
site of the deletion (M2) that up-regulated both genes, also
up-regulated both genes (Figure 6). As in the case of deletion
M2 (Figure 2), upregulation of Mrps12 was the more
dramatic, in this case by a factor of over 3. When CCAAT
boxes II, III and IV were absent, this effect was completely
masked (compare constructs ScatP, Mu3 and ScatMu in
Figure 6). It was also abolished almost completely when
only CCAAT box IV was destroyed at the same time
(compare constructs 175 and 175Mu in Figure 6) Destruction
of CCAAT boxes I, II or III individually had much milder
effects on the upregulation caused by loss of Mu3, at least
in the Mrps12 direction. We infer that the Mu3 element
causes transcriptional repression in combination with the
CCAAT box array, most potently with CCAAT box IV.
The Mu3 element contains putative binding sites for a
number of transcription factors, including NF-kB, the proges-
terone receptor and ELK. Note, however, that we did not
detect high-afﬁnity protein-binding to this region by EMSA,
nor by in vivo footprinting (Supplementary Figure 8).
The mutant constructs tested in the reporter analysis
included three carrying point mutations in the region of
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EMSA [Figure 3 but not in vivo by footprinting (Supplemen-
tary Figure 8)]. These mutations destroyed putative binding
sites for GATA-1, MYB, MTF-1 and PPAR/RXR
heterodimers. None of the mutant constructs showed substan-
tial alteration in reporter expression.
Reporter assays using mutated constructs thus conﬁrmed
the importance of the CCAAT box array for the overall
amount and directionality of transcription, and conﬁrmed
the presence of a negatively acting element within the
Mrps12 ﬁrst intron, which also requires the CCAAT box
array for activity.
DISCUSSION
In this study, we used reporter analysis, EMSA and in vivo
footprinting to identify an array of four CCAAT box elements
governing the extent and directionality of transcription of the
oppositely transcribed genes Mrps12 and Sarsm from their
common intergenic promoter region in mouse cells and
Table 1. Altered ratio of expression in the Mrps12 and Sarsm directions in
response to destruction of one or multiple CCAAT box elements
Construct CCAAT box destroyed Expression ratio
a Total expression
b
WT None 3.5 129
38 I 0.8 131
86 II 2.7 74
126 III 2.6 71
175 IV 9.3 211
ScatA I + II 0.5 106
ScatG I + III 0.4 101
ScatD I + IV 1.6 134
ScatB II + III 2.0 85
ScatC II + IV 5.6 48
ScatE III + IV 11.0 85
ScatN II + III + IV 4.2 66
ScatF I + III + IV 1.0 35
ScatV I + II + IV 1.7 38
ScatP I + II + III 0.5 188
ScatH I + II + III + IV 0.9 19
aRatio of expression in the Mrps12 direction to that in the Sarsm direction.
bArbitrary units, as defined in legend to Figure 2, where wild-type expression
in the Mrps12 direction represents 100 U of expression.
Figure 6. Reporter analysis of mutated versions of the Mrps12-Sarsm bidirectional promoter. The main features of the promoter region are reproduced from
Figure 1. The intact promoter elements remaining in each reporter construct are indicated by open circles (CCAAT boxes) and filled diamonds (NRF-2 site),
aligned with the schematic map. The locations of other, specific sets of point mutations introduced at other sites are shown by crosses. For details of mutations
and all constructions see Supplementary Table 1 and Supplementary Figure 9b. Expression in the two directions was calculated and plotted as in Figure 2. Note
that for the point mutation series, all constructs were oriented in the same manner.
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strand, but those at each end appear to direct the transcriptional
apparatus to initiate at the opposite end of the intergenic
region. The two CCAAT boxes in the middle of the array
appear to have weaker binding afﬁnity and are suggested to
function as accessory elements. The main transcription factor
implicated in this regulation is NF-Y. Weaker or inconclusive
evidence was obtained for the involvement of other factors (C/
EBP, NRF-2, AP-1, plus two unidentiﬁed factors), but their
role appears to be minor. The pattern of protein-binding to
the promoter, inferred from in vivo footprinting, appears simi-
lar in cultured ﬁbroblasts and solid tissues.
Transcriptional versus post-transcriptional regulation
of Mrps12 and Sarsm
Quantitative RT–PCR showed that the steady-state levels of
Sarsm and Mrps12 mRNAs are similar in cultured 3T3
cells, but reporter assays consistently showed a 4-fold greater
expression in the Mrps12 direction, in constructs completely
lacking the coding sequences and 30-UTR segments of the
mRNAs. The relative mRNA levels from the two genes tran-
scribed in the natural setting is, thus, dramatically different
from the relative levels of the two luciferase reporters
directed by the cloned promoter. In principle, this could
reﬂect an important contribution from post-transcriptional
regulation, e.g. at the level of mRNA stability or, alterna-
tively, an inﬂuence of transcription-regulatory elements
located far from the proximal promoter, perhaps up to tens
of kilobases away. Obviously, the latter cannot be ruled out
other by an exhaustive study of the entire chromosomal
region using reporter methodology. NRF-1-like recognition
elements within the introns of Sarsm would be one candidate
for such activity worthy of special attention.
Nevertheless, we favour the idea that the relative levels of
the two mRNAs are mainly adjusted post-transcriptionally.
In previous studies we obtained evidence for regulation of
Mrps12 at the levels of translation and alternative splicing
(8). Previous studies also showed that Sarsm was ubiquitously
expressed, although at different levels depending on the tissue
(4). Whilst transcription may favour the expression of Mrps12,
post-transcriptional regulation, probably at the level of mRNA
stability, would adjust the relative levels of the two mRNAs
according to physiological needs. The need for the synthesis
of the two gene products should differ between growing and
quiescent cells. Whereas Sarsm is a soluble enzyme, Mrps12
is a component of a stable particulate structure, the small
mitoribosomal subunit. In rapidly proliferating cells, Mrps12
synthesis is clearly translationally up-regulated (8), and
mRNA stability may also play a role in this. Both Mrps12
and Sarsm mRNAs vary in abundance between tissues (4,8),
and the patterns are distinct, although this might also reﬂect
species differences. Conversely, in the present study, in vivo
footprinting revealed similar patterns of protein occupancy of
the promoter region in different tissues. This supports the idea
that tissue-differences in the levels of these two mRNAs are
effected post-transcriptionally.
Transcriptional regulation by NF-Y
Nuclear genes for mitochondrial proteins involved OXPHOS
or mitochondrial gene expression are governed by ubiquitous
transcription factors able to gear expression to the demands
of cellular growth or respiration. In mammals, the most
prominent of these are nuclear respiratory factors 1 and
2 [Ref. (13)]. In yeast, however, the heterotrimeric CCAAT
box-binding factor composed of the proteins Hap2p, Hap3p
and Hap5p (27,28), augmented by the Hap4p activator
protein (29,30) is the most important co-regulator of nuclear
genes involved in mitochondrial biogenesis and respiratory
function (14–16). The present study provides a bridge
between these observations, by identifying the mammalian
homologue of the Hap2/3/5 complex, NF-Y (31), as a key
regulator of two genes of the mitochondrial translational
machinery in mouse cells.
CCAAT boxes I and IV of the Mrps12-Sarsm promoter
show a good match to the consensus binding site for NF-Y
(32), whereas CCAAT boxes II and III of the array, which
were inferred to show weaker binding and to function
most likely as accessory elements, show a weaker match to
the consensus (Supplementary Figure 10). ChIP analysis
also conﬁrmed that NF-Y is bound to the promoter in vivo.
In vivo footprinting showed evidence for occupancy of
all four CCAAT boxes of the array, although the results of
EMSA suggest that protein-binding to each site may be
mutually exclusive. Moreover, reporter analysis conﬁrmed
that binding at each site confers a different transcriptional
selectivity. Since all four CCAAT boxes are oriented on
the same strand, we propose that NF-Y binding is able to
recruit the transcriptional apparatus at this promoter region
in two oppositely oriented ways. NF-Y is known to have
this property more generally: approximately half of all NF-
Y binding sites in vertebrates are oriented with ATTGG on
the coding strand, especially when TATA is absent, as
here (32).
Based on our ﬁndings, NF-Y binding at CCAAT box I,
especially when present together with its accessory site
CCAAT box II, appears to favour transcription in the Mrps12
direction, whereas binding at CCAAT box IV, in conjunction
with either of CCAAT boxes III or II, favours transcription in
the opposing, Sarsm direction. In human (Supplementary
Figures 1 and 10), CCAAT box II shows a better match to
the NF-Y consensus than CCAAT box I, so it will be interest-
ing to compare the regulatory properties of these elements in
human cells, using similar assays.
Regulation of transcription by an array of precisely spaced
CCAAT elements interacting with NF-Y has previously been
reported for genes linked to the cell division cycle, such as
cyclin B2 (33), cdc25C (34) and thymidine kinase (35). How-
ever, this is, to our knowledge, the ﬁrst report of such an array
as the key component of a bidirectional promoter, although
the mouse promoter for O-sialoglycoprotein endopeptidase
and APEX endonuclease may represent a second example
(36). The inherent bidirectionality of the action of NF-Y
makes it an ideal transcription factor to govern bidirectional
promoters. The presence of multiple recognition elements
favouring transcription in each direction should constitute
an additional failsafe mechanism to ensure that both genes
are transcribed.
Distortion of promoter DNA appears to be a common
mechanism by which NF-Y activates transcription (37). The
subtly variable mobility shifts seen in vitro (Figure 4b),
plus the detection of adjacent hyperaccessible and protected
674 Nucleic Acids Research, 2007, Vol. 35, No. 2sites within and adjacent to the CCAAT box array (Figure 5)
suggest that such bending occurs also within the Mrps12-
Sarsm promoter.
Possible roles of other regulatory factors
The Mrps12-Sarsm promoter region contains putative binding
sites for several other transcription factors, including AP-1
and NRF-2. Occupancy of these sites in vivo was suggested
by in vivo footprinting, and reporter analysis conﬁrmed that
they contribute, albeit modestly, to the total transcriptional
activity in both directions, despite our failure to detect
protein-binding at these sites by EMSA.
As well as facilitating assembly of the basal transcription
machinery, NF-Y can recruit other transcription factors
(38–40). Recruitment of SREBP-1a to the rat farnesyl
diphosphate synthase promoter is dependent on NF-Y, but
SREBP-1a binding does not require continued binding of
NF-Y to the DNA (40). Transient NF-Y binding, resulting
in the recruitment of other factors, may be one way to
reconcile our EMSA and in vivo data. It is also possible
that NF-Y binding in the intergenic region may facilitate
transcription factor binding to more distant binding sites,
e.g. the putative NRF-1 binding sites within Sarsm coding
or intronic DNA.
In several experiments, we found evidence for an interac-
tion between the NF-Y bound complex and C/EBP, especially
in liver (Figure 4e) or when CCAAT box IV was disrupted
(Figure 4d). Mrps12-Sarsm may thus be co-regulated by
these factors, as previously inferred for mouse adiponectin
(41), human microsomal epoxide hydrolase, EPHX1 (42)
and mouse amelogenin (43).
In other genes studied, e.g. rat cytochrome c oxidase
subunit IV (44), loss of NRF-2 binding usually causes a dra-
matic drop in transcription. In contrast, destruction of
the NRF-2 binding site in the Mrps12-Sarsm promoter
entrains only a 50% decrease in transcription (Figure 6).
However, NRF-2 might still be important for ﬁne-tuning
expression to physiological conditions, since it is regulated
by reactive oxygen species (45,46), and is also translocated
to the nucleus in neurons under stimulation (47). Another
possibility is that, in this promoter, NRF-2 is redundant
with other transcription factors (e.g. C/EBP, NRF-1, AP-1),
any or all of which may be recruited by NF-Y bound to the
CCAAT box array.
We found evidence for two other protein–DNA interac-
tions within the optional Mrps12 ﬁrst intron that may
inﬂuence transcription, although in vivo and in vitro ﬁndings
were not fully consistent. A clear EMSA signal was obtained
that was speciﬁcally competed by an oligonucleotide
covering the splice donor site. However, we found no
evidence from in vivo footprinting for occupancy of this
region in vivo, nor any substantial effect of point mutations
in it on the expression of reporter genes. The possible role
of a factor binding at this site in vivo remains open.
Further downstream, in the phylogenetically conserved
portion of the intron, we found evidence from reporter
analysis for a negatively acting element. The identity
of any protein(s) interacting with this site remains unclear.
No sequence-speciﬁc binding to this region was revealed by
EMSA, but the effect of mutating the site was abolished
by concomitant disruption of the CCAAT box array, most
notably in a construct in which CCAAT box IV was
destroyed (compare constructs 175 and 175 Mu in
Figure 6). Therefore, whatever protein(s) are involved most
likely act only in combination with NF-Y and possibly
other factors. If sequence-speciﬁc contacts are involved,
they do not appear to involve any guanines.
In yeast, the glucose-responsiveness of genes controlled
by the Hap2p/Hap3p/Hap5p complex is conferred by the
differentially transcribed activator protein Hap4p (48). In
mammals, there appears to be no homologue of Hap4p, and
instead NF-Y interacts directly with the transcriptional
apparatus and/or other transcription factors, as part of more
diverse regulatory programmes than simply the switching
on of mitochondrial biogenesis during the yeast diauxic
shift. However, as we document here, ensuring the supply
of at least two key proteins of the machinery of mitochon-
drial protein synthesis is also one of the tasks of NF-Y in
mammals.
Mrps12-Sarsm as a general paradigm for
bidirectional promoters
Approximately 2000 bidirectional promoters are found in
mammalian genomes, accounting for about 10% of all
genes (5,6). As in the majority of such cases, the bidirectional
promoter governing Mrps12 and Sarsm is GC-rich,
constitutes a CpG island and is TATA-less. This organization
is also conserved phylogenetically, at least amongst mam-
mals. Like many such gene pairs, e.g. chaperonins HSP60
and HSP10 (49) the two gene products are functionally
related.
The main regulatory elements have been identiﬁed in only
a handful of examples of such bidirectional promoters. This
study therefore represents a useful paradigm, both methodo-
logically and in terms of its major ﬁndings, for analyzing
the transcriptional regulation of an important class of promot-
ers. A complete understanding of this regulation is a prereq-
uisite of any attempt to manipulate the expression of just one
member of such gene pairs, with biotechnological or
biomedical applications in view.
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Supplementary Data are available at NAR online.
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